QQQ   426.54 (+0.16%)
AAPL   167.62 (-0.23%)
MSFT   409.85 (-0.48%)
META   508.57 (+2.91%)
GOOGL   155.99 (+0.33%)
AMZN   181.52 (+0.13%)
TSLA   149.85 (-3.60%)
NVDA   856.78 (+1.96%)
AMD   155.85 (+1.19%)
NIO   4.01 (+2.56%)
BABA   69.29 (+0.68%)
T   16.20 (+0.50%)
F   12.10 (+0.50%)
MU   113.00 (-2.86%)
GE   156.55 (+0.57%)
CGC   7.77 (+19.72%)
DIS   113.45 (+0.45%)
AMC   2.93 (-1.68%)
PFE   25.31 (-0.43%)
PYPL   62.51 (-1.19%)
XOM   118.73 (+0.08%)
QQQ   426.54 (+0.16%)
AAPL   167.62 (-0.23%)
MSFT   409.85 (-0.48%)
META   508.57 (+2.91%)
GOOGL   155.99 (+0.33%)
AMZN   181.52 (+0.13%)
TSLA   149.85 (-3.60%)
NVDA   856.78 (+1.96%)
AMD   155.85 (+1.19%)
NIO   4.01 (+2.56%)
BABA   69.29 (+0.68%)
T   16.20 (+0.50%)
F   12.10 (+0.50%)
MU   113.00 (-2.86%)
GE   156.55 (+0.57%)
CGC   7.77 (+19.72%)
DIS   113.45 (+0.45%)
AMC   2.93 (-1.68%)
PFE   25.31 (-0.43%)
PYPL   62.51 (-1.19%)
XOM   118.73 (+0.08%)
QQQ   426.54 (+0.16%)
AAPL   167.62 (-0.23%)
MSFT   409.85 (-0.48%)
META   508.57 (+2.91%)
GOOGL   155.99 (+0.33%)
AMZN   181.52 (+0.13%)
TSLA   149.85 (-3.60%)
NVDA   856.78 (+1.96%)
AMD   155.85 (+1.19%)
NIO   4.01 (+2.56%)
BABA   69.29 (+0.68%)
T   16.20 (+0.50%)
F   12.10 (+0.50%)
MU   113.00 (-2.86%)
GE   156.55 (+0.57%)
CGC   7.77 (+19.72%)
DIS   113.45 (+0.45%)
AMC   2.93 (-1.68%)
PFE   25.31 (-0.43%)
PYPL   62.51 (-1.19%)
XOM   118.73 (+0.08%)
QQQ   426.54 (+0.16%)
AAPL   167.62 (-0.23%)
MSFT   409.85 (-0.48%)
META   508.57 (+2.91%)
GOOGL   155.99 (+0.33%)
AMZN   181.52 (+0.13%)
TSLA   149.85 (-3.60%)
NVDA   856.78 (+1.96%)
AMD   155.85 (+1.19%)
NIO   4.01 (+2.56%)
BABA   69.29 (+0.68%)
T   16.20 (+0.50%)
F   12.10 (+0.50%)
MU   113.00 (-2.86%)
GE   156.55 (+0.57%)
CGC   7.77 (+19.72%)
DIS   113.45 (+0.45%)
AMC   2.93 (-1.68%)
PFE   25.31 (-0.43%)
PYPL   62.51 (-1.19%)
XOM   118.73 (+0.08%)

Inhibitor Therapeutics (INTI) Earnings Date, Estimates & Call Transcripts

$0.07
0.00 (0.00%)
(As of 04/17/2024 ET)

Earnings Summary

Upcoming
Earnings Date
May. 10Estimated
Actual EPS
(Mar. 29)
-$0.01 Missed By -$0.01
Skip Charts & View Estimated and Actual Earnings Data

INTI Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

INTI Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

INTI Earnings Date and Information

Inhibitor Therapeutics last posted its earnings results on March 29th, 2024. The reported ($0.01) earnings per share for the quarter. Inhibitor Therapeutics has generated ($0.01) earnings per share over the last year (($0.01) diluted earnings per share). Inhibitor Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Friday, May 10th, 2024 based off prior year's report dates.

Inhibitor Therapeutics Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
5/10/2024
Estimated)
------- 
3/29/2024Q4 2023-($0.01)($0.01)($0.01)--

Inhibitor Therapeutics Earnings - Frequently Asked Questions

When is Inhibitor Therapeutics's earnings date?

Inhibitor Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Friday, May 10th, 2024 based off last year's report dates. Learn more on INTI's earnings history.

How much profit does Inhibitor Therapeutics generate each year?

Inhibitor Therapeutics (OTCMKTS:INTI) has a recorded net income of -$3.03 million. INTI has generated -$0.01 earnings per share over the last four quarters.


More Earnings Resources from MarketBeat

This page (OTCMKTS:INTI) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners